PKCa and Ets1 are both associated with breast cancer progression. Our previous studies suggested that these proteins are likely to functionally interact with one another. Here, we show that attenuation of endogenous PKCa expression (siPa) by RNA interference leads to reduced Ets1 protein expression in a variety of cancer cells. Pulse-chase experiments and treatment with proteasome inhibitor MG-132 revealed that siPa interferes with both Ets1 protein synthesis and stability. The effect of siPa on Ets1 expression could be partially prevented by KN-93, suggesting that calcium/calmodulin-dependent kinase II (CaMKII), a modulator of Ets1 activity, may play a role in PKCa-dependent Ets1 regulation. In contrast, Ets1-regulating kinases ERK1/ 2 were not found to be involved in this process. To assess the importance of the PKCa/Ets1 interaction, we compared the biological responses of MDA-MB-231 cells to PKCa-and Ets1-specific siRNAs (siE1). While only siPa induced changes in cellular morphology and anchorage-independent growth, both siRNAs similarly affected cellular responses to the antitumor drug mithramycin A and to UV light. Microarray analyses further showed that the expression of a certain set of genes was equally affected by siPa and siE1. The data suggest that Ets1 serves as an effector for PKCa to fulfil certain functions in cancer cells.
Introduction
Ets1 is a member of the Ets transcription factor family that is defined by a common DNA-binding domain, the Ets domain (Sharrocks et al., 1997; Graves and Petersen, 1998) . Ets proteins have been shown to be able to activate many genes (Sementchenko and Watson, 2000) and to be deregulated in various diseases, including cancer (Dittmer and Nordheim, 1998; Foos and Hanser, 2004; Hsu et al., 2004) . Ets1 is overexpressed in a wide variety of invasive cancer cells and its expression in tumor cells or in tumor-associated vascular or avascular stroma often correlates with poor prognosis (Dittmer, 2003) . How Ets1 is regulated in tumor cells is still not well understood. GTPase Ras and Ca/calmodulindependent kinase II (CaMKII) have been shown to modulate Ets1 protein activity. Ras increases Ets1 transcriptional activity through ERK1/2 (Yang et al., 1996) , which phosphorylate Ets1 at a single threonine within the N-terminal domain (Seidel and Graves, 2002) . CaMKII is able to mediate calcium-dependent inactivation of Ets1 DNA-binding activity (Pognonec et al., 1988) by phosphorylating the exon VII domain of Ets1 (Cowley and Graves, 2000) . DVII-Ets1 is devoid of this domain, rendering this natural splicing variant of Ets1 resistant to CaMKII. While being abundant in T-leukemic cells, DVII-Ets1 is barely expressed in invasive breast cancer cells .
We have recently reported that protein kinase Ca (PKCa) is able to modulate Ets1 activity in breast cancer cells . PKCa belongs to the PKC family of structurally related serine-threonine kinases. This family is divided into three groups, the conventional cPKCs (a, bI, bII and g), the novel nPKCs (d, e, Z, m and y), and the atypical aPKCs (i and z) (reviewed in Liu and Heckman, 1998; Mellor and Parker, 1998) . Conventional PKC isotypes, such as PKCa, are activated by calcium and 1,2-diacylglycerol and phorbol ester (PMA). Upon activation, the PKC proteins associate with the phosphatidylserines of membranes, now able to phosphorylate a variety of substrates. Like Ets1, PKCa is primarily expressed in invasive cancer cells (Platet et al., 1998; Lindemann et al., 2003) . It is able to induce an aggressive neoplastic phenotype when overexpressed (Ways et al., 1995) and has been shown to contribute to tumor growth in mice (Sioud and Sorensen, 1998) . PKCa-specific inhibitors have entered phase I/II clinical studies underscoring the significance of PKCa in cancer research.
Since PKC inhibitors stauromycin and calphostin C abrogates Ets1 expression in breast cancer cells (Lindemann et al., 2001) , it is possible that PKCa not only modulates Ets1 activity but also interferes with its expression. To explore this possibility, we downregulated endogenous expression of PKCa by RNA interference. We found that, in all cancer cell lines studied, the Ets1 protein level decreased along with the decline in PKCa expression. Our data further suggest that CaMKII, but not Erk1/2, is involved in this PKCa effect on Ets1. In addition, we present evidence for Ets1 being an effector of PKCa in MDA-MB-231 breast cancer cells.
Results

Suppression of endogenous PKCa expression results in downregulation of the Ets1 protein level
To suppress endogenous PKCa expression, we designed a PKCa-specific small interference (si) RNA (siPa). We first determined the ability of siPa to reduce PKCa RNA and protein levels in MDA-MB-231 breast cancer cells. As measured by quantitative RT-PCR, treatment of cells with siPa for 3 days resulted in downregulation of the endogenous PKCa RNA level by eight-fold ( Figure 1a ). In contrast, control siRNAs (siE1, siLuc, siElf), which were designed to target Ets1-, luciferase-or Elf-1-specific RNAs, respectively, showed no effect on the PKCa-specific RNA levels. Western blot analyses using a PKCa-specific antibody revealed that siPa also substantially reduced the protein level of PKCa ( Figure 1b , lanes 2, 6 and 8). Again, no effect on PKCa expression was found when one of the other siRNAs (lanes 3, 5 and 9) or when no siRNA (lanes 1, 4 and 7) was used. By reprobing the blot with antibodies against Sp1 and/or Sp3, it could be shown that equal amounts of protein was loaded onto the gel. We also explored the possibility that siPa might affect the expression of the related kinases PKCd and PKCe. However, none of these kinases showed reduced protein levels in response to siPa (Figure 1c ). We next studied the ability of siPa to interfere with ectopically expressed PKCa. At 2 days after the first transfection with siPa or siLuc, we transfected the same MDA-MB-231 cells again with an expression plasmid carrying the coding region for the catalytic domain of the human PKCa protein (PKCa-CAT). Cells that contained the PKCa-specific siRNA produced substantially less PKCa-CAT protein than those cells treated with siLuc ( Figure 1d ). Collectively, these data indicate that siPa was able to efficiently and specifically suppress the expression of PKCa.
We next tested the ability of siPa to interfere with Ets1 expression in MDA-MB-231 cells. As analysed by quantitative RT-PCR, no significant effect of siPa on the Ets1 RNA level was observed (Figure 2a ). Nor did siLuc or siElf influence the level of Ets1-specific transcripts. However, as expected, the Ets1-specific siRNA siE1 significantly reduced the Ets1 RNA level. When we analysed protein expression by Western blot analysis, the outcome was different. The results of three representative experiments (out of 14 independent experiments) are shown in Figure 2b . In all experiments, siPa substantially reduced Ets1 protein expression. This effect was as strong as that of siE1 (compare lane 6 and 7). However, in contrast to siE1, siPa affected Ets1 expression exclusively on the protein level. These data suggest that PKCa regulates Ets1 activity in MDA-MB-231 by interfering with its expression on the posttranscriptional level.
To investigate whether the PKCa-dependent Ets1 expression is a unique feature of MDA-MB-231 cells, we also studied the effect of siPa on Ets1 in other Ets1-expressing cancer cell lines (MDA-MB-435 breast cancer, OsA-CL osteosarcoma, SK-Mel melanoma and Jurkat T-leukaemic cells). In all these cell lines, siPa was able to sufficiently suppress the PKCa protein expression (Figure 2c) . Reprobing of the Western blot with anti-Ets1 antibody revealed that siPa also strongly downregulated the Ets1 protein level, suggesting that PKCa also regulates Ets1 expression in these cancer cells. When we compared the level of Ets1 and PKCa protein expression between the cell lines, it was striking that the PKCa protein level correlated well with that of Ets1 is an effector of PKCa M Vetter et al Ets1 (Figure 2d ). Also, serum-and zinc-induced upregulations of the Ets1 protein level in SK-Mel cells were accompanied by enhanced expression of PKCa (Figure 2e , compare lanes 1 to 5 and lanes 6 with 7). These observations support the notion that the expression of Ets1 and PKCa are linked in cancer cell lines. Interestingly, in contrast to PKCa expression, the protein level of PKCe showed an inverse relationship to that of Ets1 ( Figure 2d ). As has been reported for intestinal epithelial cells (Song et al., 2002) , PKCa and PKCe may have opposing effects in cancer cells. Collectively, these data suggest that, in different types of cancer cells, PKCa regulates the expression of Ets1.
In Jurkat cells, siPa had an additional effect on the Ets1 protein, as it induced the appearance of a slower migrating form of Ets1 (pp) (Figure 2c, lane 10) . A similar Ets1 form was also observed in SK-Mel cells when these cells recovered from serum starvation at a time when the PKCa protein level was still low (Figure 2e , lanes 3 and 4). It disappeared when PKCa expression was fully re-established (lane 5). A decrease in the mobility of the Ets1 protein can be caused by phosphorylation (Pognonec et al., 1988; Ballschmieter et al., 2003) . We, therefore, incubated SK-Mel protein extracts containing the slower migrating Ets1 form with alkaline phosphatase. Treatment with this enzyme resulted in the disappearance of the slower migrating Ets1 form, while the level of the regular Ets1 form increased (Figure 2e , lane 10). This shows that the slower migrating Ets1 protein was indeed a phosphorylated form of Ets1. These data suggest that PKCa not only upregulates the expression of Ets1 but also prevents Ets1 phosphorylation. Jurkat cells express the natural splicing Ets1 variant DVII-Ets1 (p42-Ets1) which lacks the exon VII domain. Interestingly, siPa did neither affect its expression, nor did it affect the mobility of this Ets1 protein (Figure 2c , compare lanes 9 and 10). Since the exon VII domain is a major phosphorylation site, it is possible that PKCa interferes with exon VII-dependent phosphorylation.
siPa interferes with Ets1 protein synthesis and stability
We next explored the possibility that siPa interferes with Ets1 protein stability. We first analysed the effect of the proteasome inhibitor MG-132 on Ets1 protein expression in the presence or absence of siPa. As shown in Figure 3a , MG-132 almost completely reversed the effect of siPa on the Ets1 protein level (compare lanes 3 and 4), while it only slightly increased Ets1 expression under control conditions (compare lanes 1 and 2). In a second approach, we analysed Ets1 protein stability directly by pulse-chasing with 35 S-methionine followed by immunoprecipitation with a rabbit anti-Ets1 antibody agarose conjugate. The data show that, in the presence of siPa, Ets1 protein neo-synthesis is reduced (Figure 3b , upper panel, compare lanes 1 and 4) and the newly synthesized Ets1 protein is degraded more rapidly (Figure 3b , upper panel, Figure 3c ). To show that, also under the pulse-chase conditions, the total Ets1 protein level was downregulated by siPa, Ets1 proteins were visualized by a mouse anti-Ets1 antibody (Figure 3b , middle panel, compare lanes 1-3 with lanes 4-6). An anti-rabbit peroxidase conjugate was used to demonstrate that equal amounts of the anti-Ets1-agarose conjugate were added to each sample (Figure 3b , lower panel). Collectively, these data show that siPa affects both Ets1 protein synthesis and Ets1 protein stability.
Suppression of CaMKII activity partially rescues Ets1 protein expression in the presence of the PKCa-specific siRNA
The data suggest that PKCa may regulate Ets1 expression by interfering with Ets1 phosphorylation. Ets1 is an effector of PKCa M Vetter et al Phosphorylation can have positive or negative effects on the activity of the Ets1 protein, depending on where phosphorylation on the Ets1 protein has taken place (Pognonec et al., 1988; Yang et al., 1996; Cowley and Graves, 2000; Seidel and Graves, 2002) . Phosphorylation at the N-terminus by ERK1/2 leads to Ets1 superactivation (Yang et al., 1996; Seidel and Graves, 2002) , whereas phosphorylation of the exon-VII domain by calcium or CaMKII results in inhibition of the Ets1 DNA-binding activity (Pognonec et al., 1988; Cowley and Graves, 2000) . In previous studies, PKCa has been shown to interfere with the activities of ERK1/2 as well as with that of CaMKII. For example, PKCa has been shown to indirectly induce phosphorylation and activation of ERK1/2 through the Raf/MEK1 pathway (Soh et al., 1999) . PKCa has also been demonstrated to hinder CaMKII from phosphorylating the N-methyl-Daspartate (NMDA) receptor (Gardoni et al., 2001) .
To study the importance of ERK1/2 for the PKCa effect on Ets1 expression, we analysed changes in the ERK1/2 activation status in MDA-MB-231 cells in the presence and absence of siPa by using an antibody that recognizes the Thr202/Tyr204-phosphorylated forms of these kinases (pp44 and pp42). In agreement with previous reports (Zhou et al., 1998) , ERK1/2 activities were found to be much higher in MDA-MB-231 cells ( Figure (Platet et al., 1998) . It is, therefore, possible that, by activating the Raf/MEK-1 pathway, the permanently activated PKCa is responsible for the high basal ERK1/2 activity in these cells. We tested this hypothesis by using siPa. As shown in Figure 4a , siPa failed to significantly reduce ERK1/2 phosphorylation relative to S-methionine were carried out in the presence of either siElf or siPa. Ets1 proteins were immunoprecipitated by a rabbit anti-Ets1-agarose conjugate and blotted onto a PVDF membrane. After exposure to an X-ray film to determine the 35 S activity, the blot was sequentially probed with a murine anti-Ets1 antibody/anti-mouse peroxidase conjugate to detect the Ets1 protein and with an anti-rabbit peroxidase conjugate to visualize the heavy chain of the rabbit anti-Ets1 antibody used to precipitate Ets1. . This shows that PKCa is not responsible for the high basal activity of ERK1/2 in MDA-MB-231 cells. It also implies that it is unlikely that ERK1/2 are involved in the regulation of Ets1 by PKCa. This notion is supported by the observation that complete inhibition of ERK1/2 phosphorylation by U0126 had no effect on Ets1 expression (Figure 4b , compare lanes 1,2 with lanes 3,4).
We next tested the effect of CaMKII inhibition on PKCa-dependent Ets1 expression. CaMKII can be specifically inhibited by the small molecule KN-93. MDA-MB-231 cells were incubated with siPa or siLuc for 3 days and then treated with KN-93 for 4 h. In the presence of the control siRNA siLuc, KN-93 had no effect on the Ets1 protein level (Figure 4d , compare lanes 1 and 3), whereas KN-93 partially rescued Ets1 protein expression in siPa-treated cells (compare lanes 1 and 4). Importantly, KN-93 did not affect Ets1-RNA levels (data not shown). These data demonstrate that KN-93 counteracted the effect of siPa, suggesting that CaMKII may play a role in the PKCa-dependent regulation of Ets1 expression.
PKCa and Ets1-specific siRNAs similarly modulate cellular responses to mithramcyin A and UV light
We next wanted to know what biological consequences the regulation of Ets1 expression by PKCa has for the tumor cells. To address this issue, we compared the effects of the PKCa-and Ets1-specific siRNAs on biological responses of MDA-MB-231 cells. One obvious effect of siPa was a change in the morphology of these cells. At 3 days after transfection with siPa, the majority of MDA-MB-231 cells displayed prominent thin long filopodia (Figure 5a ). To demonstrate that the cells displaying filopodia were transfected cells, we cotransfected cells with siPa and a GFP expression Ets1 is an effector of PKCa M Vetter et al plasmid. As was found when electroporating the GFP plasmid alone , approximately 50% of the GFP/siPa-transfected MDA-MB-231 cells were staining positive for GFP after overnight incubation. After two more days, when filopodia were first visible, still approximately 35% of the cells contained GFP. Most of these cells had developed filopodia (Figure 5b ), demonstrating that those cells that showed filopodia-like protrusions were indeed transfected cells. In contrast to siPa-treated cells, cells grown in the presence of siElf-1 or siE1 rarely formed filopodia (Figure 5a ) indicating that the siPa effect on cellular morphology was independent of Ets1.
In another approach, we compared the effect of the different siRNAs on anchorage-independent growth of MDA-MB-231 cells. As shown in Figure 5c , siPa reduced colony formation by 50% relative to siElf. A similar reduction in anchorage-independent growth of mammary adenocarcinoma MTLn3 cells was observed, when Go¨6976 was used to inhibit PKCa, the only classical PKCs that is expressed in these cells (Huigsloot et al., 2003) . In contrast to siPa, siE1 rather slightly increased anchorage-independent growth (Figure 5c ), suggesting that also this siPa effect did not involve Ets1.
We next analysed the capabilities of siPa and siE1 to modulate sensitivity of MDA-MB-231 cells to the antitumor drug mithramycin A (Remsing et al., 2003) and UV light. Both PKCa and Ets1 have been reported to be involved in stress-induced responses. For example, PKCa has been shown to render tumor cells resistant to a variety of cytotoxic agents (Budworth et al., 1997; Orlandi et al., 2003; Soh et al., 2003) . Ets1, on the other hand, was found to be play a key role in UV-light-induced apoptosis in embryonic stem cells (Xu et al., 2002) . As shown in Figure 6a , siPa and siE1 similarly increased the sensitivity of MDA-MB-231 cells to mithramycin, whereas siElf had no effect. In the absence of mithramycin, no difference in the effect of the different siRNAs on cell survival was observed (data not shown). When MDA-MB-231 cells were exposed to UV light, they rapidly detached from their substratum. However, no signs of apoptosis could be observed. This suggests that the UV light predominantly affected the adhesive properties of these cells. Consistent with this observation, UV light was found to alter the expression of adhesion-relevant genes in keratinocytes (Sesto et al., 2002) . siPa and siE1 similarly reduced UV-dependent displacement of MDA-MB-231 cells relative to the untreated control (Figure 6b and c) . In contrast, siElf-1 rather promoted cell detachment. These data show that siE1 can mimic some, but not all siPa effects on Anchorage-independent growth. Cells transfected with siElf, siPa or siE1 were grown in agarose as described under Materials and methods. Colonies were counted 5 days after transfection by using microscopy Figure 6 Similar effects of SiPa and siE1 on cellular responses to mithramycin and UV light. (a) siPa and siE1 increase sensitivity of MDA-MB-231 cells to mithramycin. MDA-MB-231 cells transfected with siElf, siPa, siE1 or with no siRNA were grown for 3 days in the absence and for another 3 days in the presence of 10 mM mithramycin A. As a measure of cell survival, the number of remaining adherent cells was determined by using microscopy. Bars represent the average value of three independent experiments. (b,c) siPa and siE1 similarly increase resistance to UV light. At 3 days after transfection with with siElf, siPa, siE1 or with no siRNA, growth medium was replaced by PBS and MDA-MB-231 cells were irradiated by UV light followed by a 3-hour incubation in PBS at 371C. The number of detached and of remaining adherent cells were counted by using microscopy. (b), Bars represent the average value of three independent experiments. (c) Cells were photographed by using phase-contrast microscopy. Control cells (Co) were incubated with PBS without being exposed to UV light Ets1 is an effector of PKCa M Vetter et al MDA-MB-231 cells, suggesting that Ets1 mediates certain biological activities of PKCa.
PKCa and Ets1-specific siRNA have common effects on gene expression in MDA-MB-231 cells
We explored the possibility that PKCa-and Ets1-specific siRNAs interfere with gene expression. We carried out two sets of microarrays by using the Affymetrix Human Genome U133A GeneChip and RNAs derived from two independent transfection experiments. Only those genes that showed altered expression in the presence of siE1 and siPa in both sets of arrays were considered to have responded to the reduced expression of Ets1 and PKCa. In the presence of siPa, expression of 60 genes were found to be changed. A total of 32 (53%) of these genes, as listed in Table 1 , were also identified, when cells were treated with siE1. The expression pattern of 13 of these genes were also analysed by quantitative RT-PCR (Figure 7) . The results obtained by this method are in good agreement with the microarray data.
Six genes (NQO1, MMP1, MMP9, ARPC2, ARHG-DIB and PEG10) of the 32 genes have been reported to be associated with tumor progression (Behrens et al., 2001; Sunaga et al., 2002; Lin et al., 2003; Okabe et al., 2003; Otsubo et al., 2004) . Except PEG10, all of these genes were found to be downregulated along with Ets1 and PKCa. Among the 32 genes, five genes were found that may have tumor suppressing functions (TGFB2, INSIG1, DIAPH1, PML, TSSC3) (Lee and Feinberg, 1998; Kaneda et al., 2002; Sahai and Marshall, 2002; Salomoni and Pandolfi, 2002; Samatar et al., 2002; Han et al., 2003) . All but one (TSSC3) of these genes showed expression that was inversely related to that of Ets1 and PKCa. These data are in accordance with the notion that Ets1 and PKCa promote tumor progression.
Three genes (MMP1, MMP9, RUNX1) of the 32 PKCa-and Ets1-responsive genes have previously been shown to contain Ets binding sites and to be responsive to the Ets1 protein (Ghozi et al., 1996; Baillat et al., 2002) . Another gene, SP100, has been decribed to be a modulator of Ets1 activity (Wasylyk et al., 2002; Yordy et al., 2004) . SP100 colocalizes with PML in nuclear bodies (Salomoni and Pandolfi, 2002) whose number can be regulated by Ets1 (Wasylyk et al., 2002; Yordy et al., 2004) . In contrast to SP100, PML was found to be increased in the presence of siE1 and siPa. Collectively, these data show that approximately half of the genes responsive to PKCa are also affected by Ets1, suggesting 
Also analysed by Q-RT-PCR
Ets1 is an effector of PKCa M Vetter et al that Ets1 is a major effector of PKCa-dependent gene expression.
Discussion
We have previously shown that PKC inhibitors stauromycin A and calphostin C suppress Ets1 expression in breast cancer cells (Lindemann et al., 2001) , suggesting that member(s) of the protein kinase C are involved in the regulation of Ets1 expression. We also found that one of the PKC members, PKCa, supports Ets1-dependent transcription in these cells and that this PKC subtype is able to phosphorylate Ets1 in vitro . This prompted us to study whether PKCa also plays a role in the regulation of Ets1 expression. By using RNA interference to suppress endogenous PKCa expression, we found that, along with the decline in PKCa levels, the Ets1 protein level substantially decreased. This could not only be demonstrated for breast cancer cells but also for osteosarcoma, melanoma and leukemia cells. In contrast to the Ets1 protein level, the Ets1 RNA level was not significantly reduced by the PKCa-specific siRNA. Also, the proteasome inhibitor MG-132 rescued Ets1 protein expression in the presence of siPa. Furthermore, in Jurkat cells, expression of full-length Ets1, but not that of the splicing variant DVII-Ets1 was affected by siPa. These data combined suggest that siPa modulated Ets1 expression on the post-transcriptional level. Data obtained from pulse-chase experiments confirmed this hypothesis in that they show a decrease in the Ets1 protein stability in response to siPa. Yet, the results also showed that siPa downregulates Ets1 protein neo-synthesis, indicating that more than one mechanism is responsible for the siPa-dependent decline in Ets1 expression. The observation that siPa did not affect the Ets1 RNA level, yet decreased Ets1 protein synthesis raises the interesting question of whether siPa may interfere with the translation efficiency of the Ets1-RNA. Such a regulatory mechanism has been proposed to be responsible for the different MMP-9 protein levels observed in two sublines of a prostate carcinoma cell line (Jiang and Muschel, 2002) .
Since CaMKII inhibitor KN-93 partially rescued Ets1 expression in the presence of siPa, CaMKII is likely to be involved in PKCa-dependent regulation of Ets1 expression. In support of this notion, the splicing variant DVII-Ets1 that lacks the CaMKII exon VII target sequences (Cowley and Graves, 2000) fails to respond to siPa in Jurkat cells. Also, in the same cell line, siPa increased phosphorylation of full-length Ets1, but not DVII-Ets1. CaMKII-dependent phosphorylation of the exon VII domain can lead to decreased Ets1 protein stability (Pognonec et al., 1988) . Hence, CaMKII may be important for the siPa effect on Ets1 protein stability. One possible way how CaMKII may be involved in PKCa-dependent control of Ets1 expression is by being a target of PKCa. PKCa might counteract the inhibitory action of CaMKII on Ets1 and, thereby, increase Ets1 protein stability. There is evidence that PKCa is able to inhibit target-specific CaMKII activities. For example, it has been shown that PKCa inhibits CaMKII-dependent phosphorylation of the NMDA receptor by phosphorylating serine 1416 in the cytoplasmic tail of subunit NR2A and, thereby, preventing binding of CaMKII to its interaction site at amino acids 1412-1419 (Gardoni et al., 2001) . Similarly, PKCa might phosphorylate the CaMKII interaction site on the Ets1 protein. To the best of our knowledge, this Table 1 . The primer pairs used to determine the RNA levels of these genes are listed in Table 3 Ets1 is an effector of PKCa M Vetter et al site is not yet known. However, it may be more complicated, as we found that PKCa itself is able to phosphorylate the exon VII domain , although it is not clear whether this is a direct or indirect effect. It is possible that different phosphorylation pattern occur on the exon VII domain and that the one induced by PKCa may differ from that induced by CaMKII. In this case, PKCa-dependent phosphorylation may render the exon VII domain resistent to CaMKII-dependent phosphorylation. Alternatively, phosphorylation of Ets1 by PKCa and regulation of Ets1 expression by this kinase are independent events. Studies are ongoing to clarify this point.
The finding that PKCa regulates Ets1 expression suggest that PKCa may use Ets1 to modulate gene expression and biological responses. In agreement with this notion, we found that cellular responses to exogenous stimuli were similarly modified when either PKCa or Ets1 expression was downregulated. In addition, half of the genes that showed altered expression when the PKCa expression level was downregulated showed the same changes at reduced Ets1 expression. This suggests that Ets1 is a PKCa effectors in tumor cells.
Among the 32 genes that were responsive to PKCa as well as to Ets1 were a number of potential or known tumor promoter or tumor suppressor genes. Most of these genes changed expression in response to Ets1 and PKCa-specific siRNA in a way which is in accordance with a tumor-promoting function of Ets1 and PKCa. The Ets1-responsive genes MMP1 and MMP9 have previously been reported to be upregulated along with Ets1 in the stromal and tumoral compartments of breast cancer (Behrens et al., 2001 ). These protease genes are an essential part of the invasive program of cancers. Two other genes are linked to actin polymerization. ARPC2, the p34 subunit of the Arp2/3 complex, is downregulated when PKCa or Ets1 are suppressed. Arp2/3 is involved in the regulation of actin filament in branching and essential for actin-based motility (Carlier et al., 2003) . In invasive colorectal cancer expression of Arp2 and Arp3 is increased (Otsubo et al., 2004) . This suggests that the Arp2/3 complex is involved in tumor progression. DIAPH1, a promoter of actin polymerization and downstream effector of GTPase RhoA (Sahai and Marshall, 2002) , was found to be upregulated in the presence of Ets1 and PKCa-specific siRNAs. By inducing stable adherens junctions between cells, DIAPH1 decreases motility (Sahai and Marshall, 2002) and may have contributed to the decreased displacement of siE1-and Pa-treated MDA-MB-231 cells in response to UV light exposure. Also, fibronectin (FN1) may be involved in this effect. It plays an important role in cell-surface interaction (Goldstein and DiMilla, 2002) and was found to be strongly upregulated in the presence of Ets1 and PKCa-specific siRNAs. It is, therefore, possible that part of the effect of PKCa on cell motility and invasion is due to the Ets1-dependent activation of MMP1, MMP9 and ARPC2 expression and to the Ets1-dependent inhibition of DIAPH1 and FN1 production. Other mechanisms by which PKCa promotes motility have been reported to involve interactions with b1 integrin and with the actinbinding protein fascin (Ng et al., 1999; Anilkumar et al., 2003) . These PKCa activities do not necessarily involve changes in gene expression. Another interesting gene whose expression was affected when Ets1 or PKCa was suppressed is NQO1. Polymorphisms in the NQO1 gene are linked to lung cancer susceptibility (Sunaga et al., 2002) . NQO1 plays a role in the degradation of the tumor suppressor protein p53. Intriguingly, it stabilizes predominantly mutant p53 (Asher et al., 2003) . Mutant p53, which is expressed in MDA-MB-231 cells, cooperates with Ets1 to induce the multidrug-resistance protein MDR1 (Sampath et al., 2001) . The decreased expression of NQO1 might have contributed to the increased sensitivity of the MDA-MB-231 cells to mithramycin A in the presence of siE1 or siPa. PML, whose expression inversely correlated with that of Ets1 and PKCa is also linked to p53. It is involved in p53-dependent apoptosis (Salomoni and Pandolfi, 2002) and colocalizes with p53 nuclear bodies. Expression of Ets1 in HeLa cells were reported to decrease the number of PML-containing nuclear bodies (Wasylyk et al., 2002; Yordy et al., 2004) . Here, we found that downregulation of Ets1 or PKCa upregulated the PML RNA level. Hence, it is possible that Ets1 regulates the number of PML nuclear bodies by simply modulating PML expression on the RNA level. The expression of another nuclear body component, SP100, was shown to be altered in response to siE1 or siPa. Interestingly, SP100 has been reported to modulate the activity of Ets1 (Wasylyk et al., 2002; Yordy et al., 2004) . Particularly, SP100 was demonstrated to inhibit Ets1-dependent activation of the MMP1 promoter and to inhibit invasiveness of MDA-MB-231 cells (Yordy et al., 2004) . SP100 was found to be downregulated by siE1 or siPa in MDA-MB-231 cells suggesting that, by increasing the expression of its inhibitor, Ets1 negatively regulates its activity in these cells.
In summary, our data suggest an important function for Ets1 in PKCa-dependent tumor progression. Ets1 seems to participate in the PKCa-dependent responses to external stimuli and to a great extent mediates PKCadependent gene expression.
Material and methods
Cell lines, siRNAs and transient transfections
Cell lines (MDA-MB-231, MCF-7, MDA-MB-435, OsA-CL, SK-Mel, Jurkat T-cells) were maintained in RPMI medium (Invitrogen) supplemented with 10% fetal calf serum (Biochrom) . No antibiotics were added. Small interfering RNA (siRNAs) were purchased from Dharmacon (Table 2 ). Cells were transfected by electroporation as described (Dittmer et al., 1993) . Briefly, cells were trypsinized, washed once with RPMI medium (without serum) and resuspended in RPMI medium at a density of approximately eight million cells per ml. For each transfection, 250 ml of the cell suspension was mixed with 20 ml of an siRNA stock solution (20 mM in water) or with 20 ml water and electroporated by using a BIORAD Ets1 is an effector of PKCa M Vetter et al GenePulserX-Cell (250 V, 800 mF). After incubation on ice for 30 min, cells were transferred to a 100 mm cell culture dish (Nunc) and mixed with 8 ml growth medium. Cells were grown for 3 days before they were harvested and lysed for protein or RNA analysis. For cotransfection experiments with green fluorescent protein (GFP), 250 ml cell suspension was mixed with 20 ml siRNA plus 3 ml GFP expression plasmid pEGFP-N1 (6 mg). To analyse the effect of siPa on PKCa-CAT expression, cells were first electroporated with the siPa or siLuc, plated on 60 mm dishes, grown for 2 days and then transfected with the PKCa-CAT expression plasmid (Soh et al., 1999) by using TransFectin (Biorad). Transfection with TransFectin was carried out as follows. PKCa-CAT expression plasmid (1 ml (2 mg) or 3 ml (6 mg)) and 15 ml transfectin were separately diluted with 500 ml serum-free RPMI-medium each in a 15 ml polystyrene tube. The two solutions were mixed and incubated for 20 min at room temperature. The DNA-transfectin-RPMI mixture was then directly added to the cells after the old medium had been replaced by 2 ml fresh serum-containing medium. Following overnight incubation, cells were harvested and lysed for Western blot analyses.
Drug treatment, UV irradiation and serum starvation
Transfected MDA-MB-231 cells were grown for 3 days. , or PMA were added 4 h before harvest at a final concentration of 20 mM, 10 mM or 100 nM, respectively. For suppression of MEK1 activity, trypsinized MDA-MB-231 cells were allowed to recover for 1 h before 1 or 10 mM of U0126 (Cell Signaling Technology) was added. Control cells were treated with the appropiate amount of dimethyl sulfoxide. Cells were harvested after 5 h. To modulate ERK1/2 activity in MCF-7 cells, cells were treated with 25 nM PMA or dimethyl sulfoxide for 1 h. MEK1 activity was inhibited by addition of 25 mM PD98059 45 min prior to PMA treatment. For mithramycin A treatment, transfected cells were incubated for another 3 days in the presence of 10 mM of this drug. Each day, dead floating cells were removed by replacing the old medium by fresh mithramycin-containing growth medium. To determine cell surival, remaining adherent cells were counted by using microscopy. To analyse the effect of UV light on MDA-MB-231 cells, transfected cells were grown on 60 mm dishes for 3 days. After removal of medium and washing of the cells with PBS, the cell layer was covered with 2 ml PBS and exposed to 100 mJ/cm 2 UV light in a Stratalinker. The cells were then incubated in the same solution at 371C for up to 3 h and the relative number of detached cells vs attached cells was determined. Of note, the detached cells were still viable and able to attach again, when PBS was replaced by growth medium. To study the effect of serum on Ets1 expression, SK-Mel cells, grown to confluency for 4 days in medium supplemented with 10% serum, were incubated with serumfree medium for 3 h and harvested 0, 5, 10, 20, 40 or 90 min after addition of serum. To investigate the importance of zinc for Ets1 expression, SK-Mel cells were incubated in the absence or presence of 100 mM ZnCl 2 for 1.5 h. Alkaline phosphatase treatment of protein extracts were carried out as described .
Anchorage-independent growth
Growth medium (2 ml) containing 0.35% low-melting agarose (FMC) and 5 Â 10 4 MDA-MB-231 cells electroporated with siRNA were overlaid onto a 3 ml bottom layer of solidified 0.6% agarose/growth medium in a 60 mm dish. After 5 days, colonies were counted by using microscopy.
Western blot analyses and antibodies
Preparation of protein extracts and Western blot analyses were essentially carried out as described (Lindemann et al., 2001) . Polyclonal rabbit antibodies directed against PKCa (C-20), PKCe (C-15), Ets1 (C-20), Sp1 (PEP2) and Sp3 (D-20) were diluted 1 : 2000, 1 : 2000, 1 : 5000, 1 : 1000 and 1 : 1000, respectively, prior to use. All these antibodies were purchased from Santa Cruz. Murine monoclonal antibody against Ets1 (diluted 1 : 100) was a product of Novocastra Laboratories. For detection of ERK1/2 or phosphorylated ERK1/2, membranes were blocked with 0.5% bovine albumin, followed by an overnight incubation at 41C with a polyclonal antibody specific for p44/42 or for phospho-p44/p42 (Thr202/Tyr204) following the protocol of the manufacturer (Cell Signaling Technology). Anti-mouse and anti-rabbit peroxidase conjugates were obtained from Amersham. Quantitation of signals were carried out with AIDA image quantitation software (Fuji).
Quantitative RT-PCR
Preparation of RNA, cDNA synthesis and PCR were carried out as described (Lindemann et al., 2001) . Quantitative PCRs using a SYBR Green containing reaction mix were either run on a GeneAmp PCR System apparatus (Perkin-Elmer Applied Biosystems) or on a Biorad-iCycler. The primers that were used are listed in Table 3 .
Microarray
For microarray analyses, Affymetrix probe array type HG-U133A was used. For preparation of biotin-labeled cRNA and hybridization, the manufacturer's protocol was strictly followed. Briefly, 1-8 mg of total RNA was first reverse transcribed using a T7-Oligo(dT) promoter primer in the first-strand cDNA synthesis reaction. Following RNase H-mediated second-strand cDNA synthesis, the double-stranded cDNA was purified and transcripted into cRNA in the presence of T7 RNA polymerase and a biotinylated nucleotide analog/ribonucleotide mix. The biotinylated cRNAs were then cleaned up and fragmented. The fragmented, biotinylated cRNA (50 ng/ml) was hybridized to a HG-U133A GeneChip expression array in a hybridization buffer containing 100 mM 2-(N-morpholino)ethanesulfonic acid (MES), 1 M NaCl, Ets1 is an effector of PKCa M Vetter et al 20 mM EDTA, 0.01% Tween-20), 50 pM of a control oligonucleotide, 0.1 mg/ml herring sperm DNA, 0.5 mg/ml bovine serum albumin, 10% dimethyl sulfoxide for 16 h at 451C. After stringent washings, hybridized biotinylated cRNAs were detected by streptavidin-phycoerythrin. Microarray analyses were performed with RNAs from two independent sets of transient transfection experiments. In the first set, gene expression pattern in the presence of siE1 or siPa was compared with that in the presence siElf, while, in the second set, it was compared with that in the presence of siLuc and that in the absence of any siRNA.
Pulse-chase labeling
MDA-MB-231 cells were electroporated with siElf or siPa and plated onto 60 mm plates. After 3 days, culture medium was removed and cells were washed once with 2 ml RPMI medium lacking L-methionine and pulse-labeled with 10 MBq 35 S-L-methionine (Hartmann Analytic) in 2 ml of L-methioninefree RPMI medium for 20 min at 371C. Following replacement of the pulse-medium by 2 ml chase-medium containing RPMI medium supplemented with 10 mM cold methionine and 10% fetal calf serum, cells were incubated at 371C for 0, 30 and 60 min. Cells were scraped off, washed once with Dulbecco's phosphate-buffered saline (PBS), and lysed for nuclear extract preparation (Blumenthal et al., 1999) . Briefly, cells were resuspended in 400 ml buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol) and incubated on ice for 15 min. After cell lysis by addition of 50 ml Nonidet P-40 (NP-40) and vortexing for 10 s, nuclei were pelleted by centrifugation at 13 000 r.p.m. for 30 s at room temperature and extracted by addition of buffer C (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol). For immunoprecipitation of Ets1, 6 ml of anti-Ets1 agarose beads (12 mg anti-Ets1 antibody conjugate, Santa-Cruz) were mixed with 9 ml dilution buffer I (10 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.05% Tween-20) and added to 250 ml of nuclear extract (containing 120 mg protein), prior diluted 1 to 1 with dilution buffer II (10 mM Tris, pH 7.5, 0.12% SDS). This mixture was vigorously shaken in an Eppendorf Thermomixer at 151C for 1 h. To remove proteins that nonspecifically interacted with the agarose beads, beads were washed four times as follows. Beads were pelleted by centrifugation at 13 000 r.p.m. for 2 min, all but 50 ml of the supernatant was removed and 500 ml of washing buffer (20 mM Tris, pH 7.5, 150 mM Tris, pH 7.5, 1 mM EDTA, 0.4% NP-40, 0.2% Triton-X100, 0.1% Tween 20, 0.1% SDS) were added. Beads were recovered by centrifugation and boiled in protein sample buffer for 5 min. Samples were run on a 10% polyacrylamide gel and blotted onto a PVDF membrane. Radioactivity was detected by exposure to an X-ray film. 
